Compare PLSE & MMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | MMSI |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2015 | 1996 |
| Metric | PLSE | MMSI |
|---|---|---|
| Price | $49.42 | $88.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $56.50 | ★ $101.45 |
| AVG Volume (30 Days) | 461.2K | ★ 497.3K |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.93 |
| EPS | N/A | ★ 1.33 |
| Revenue | N/A | ★ $1,515,906,000.00 |
| Revenue This Year | $477.71 | $7.95 |
| Revenue Next Year | $233.00 | $6.07 |
| P/E Ratio | ★ N/A | $67.32 |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $12.56 | $59.74 |
| 52 Week High | $58.90 | $94.75 |
| Indicator | PLSE | MMSI |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 54.77 |
| Support Level | $49.01 | $84.66 |
| Resistance Level | $57.82 | $92.22 |
| Average True Range (ATR) | 3.03 | 2.03 |
| MACD | -0.30 | 0.22 |
| Stochastic Oscillator | 27.00 | 59.57 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.